Interferon-based treatment of chronic hepatitis C

Biochimie

Volumn 89, Issue 6-7, 2007, Pages 894-898

  Souvignet, Claude ^a   Lejeune, Olivier ^a   Trepo, Christian ^a,b,c  

^a HÔTEL DIEU   (France)

^b INSERM   (France)

^c UNIVERSITÉ LYON 1   (France)

Author keywords

HCV; Hepatitis C; Interferon; Pegylation; Ribavirin; Treatment

Indexed keywords

ALBUMIN ALPHA INTERFERON; ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; BETA INTERFERON; COLCHICINE; LIVER ENZYME; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ANOREXIA; ANTIVIRAL THERAPY; ANXIETY; ARTHRALGIA; ARTICLE; BLOOD CELL COUNT; BONE MARROW SUPPRESSION; CLINICAL TRIAL; DEPRESSION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; FATIGUE; FLU LIKE SYNDROME; GENOTYPE; HAIR LOSS; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNE SYSTEM; IMMUNOMODULATION; LIVER HISTOLOGY; MONOTHERAPY; MYALGIA; NAUSEA; REPLICON; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS GENOME; VIRUS IMMUNITY; VIRUS LOAD; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; CHRONIC DISEASE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; MODELS, BIOLOGICAL; POLYETHYLENE GLYCOLS; RIBAVIRIN; TIME FACTORS; TREATMENT OUTCOME;

HEPATITIS C VIRUS;

EID: 34347324128     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2007.04.017     Document Type: Article

References (57)

1. Alter H.J. HCV natural history: the retrospective and prospective in perspective. J. Hepatol. 43 (2005) 550-552
2. Irving W.L., Smith S., Cater R., Pugh S., Neal K.R., Coupland C.A., Ryder S.D., Thomson B.J., Pringle M., Bicknell M., and Hippisley-Cox J. Clinical pathways for patients with newly diagnosed hepatitis C - what actually happens. J. Viral Hepat. 13 (2006) 264-271
3. Camma C., Di Marco V., Lo Iacono O., Almasio P., Giunta M., Fuschi P., Vaccaro A., Fabiano C., Magrin S., Di Stefano R., Bonura C., Pagliaro L., and Craxi A. Long-term course of interferon-treated chronic hepatitis C. J. Hepatol. 28 (1998) 531-537
4. Sen G.C. Viruses and interferons. Annu. Rev. Microbiol. 55 (2001) 255-281
5. Blight K.J., Kolykhalov A.A., and Rice C.M. Efficient initiation of HCV RNA replication in cell culture. Science 290 (2000) 1972-1974
6. Frese M., Pietschmann T., Moradpour D., Haller O., and Bartenschlager R. Interferon-alpha inhibits hepatitis C virus subgenomic RNA replication by an MxA-independent pathway. J. Gen. Virol. 82 (2001) 723-733
7. Davis G.L., Balart L.A., Schiff E.R., Lindsay K., Bodenheimer Jr. H.C., Perrillo R.P., Carey W., Jacobson I.M., Payne J., and Dienstag J.L. Treatment of chronic hepatitis C with recombinant alpha-interferon. A multicentre randomized, controlled trial. The Hepatitis Interventional Therapy Group. J. Hepatol. 11 Suppl. 1 (1990) S31-S35
8. Tanno H., Fernandez J.L., Rendo P., del Pino N., Viola L., Terg R., and Perez V. Hepatitis C virus RNA and long-term response to recombinant interferon-alpha 2b in patients with chronic hepatitis C. J. Viral Hepat. 2 (1995) 97-102
9. Poynard T., Leroy V., Cohard M., Thevenot T., Mathurin P., Opolon P., and Zarski J.P. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 24 (1996) 778-789
10. Enomoto M., Tamori A., Kawada N., Jomura H., Nishiguchi S., Saibara T., Onishi S., Mochida S., and Fujiwara K. Interferon-beta plus ribavirin for patients with hepatitis C virus genotype 1: a randomised pilot trial. Gut 55 (2006) 139-140
11. Moreno-Otero R., Trapero-Marugan M., Gomez-Dominguez E., Garcia-Buey L., and Moreno-Monteagudo J.A. Is interferon-beta an alternative treatment for chronic hepatitis C?. World J. Gastroenterol. 12 (2006) 2730-2736
12. Di Bisceglie A.M., Martin P., Kassianides C., Lisker-Melman M., Goodman Z., Banks S.M., and Hoofnagle J.H. A randomized, double-blind, placebo-controlled trial of recombinant human alpha-interferon therapy for chronic non-A, non-B (type C) hepatitis. J. Hepatol. 11 Suppl 1 (1990) S36-S42
13. Saracco G., Rosina F., Torrani Cerenzia M.R., Lattore V., Chiandussi L., Gallo V., Petrino R., De Micheli A.G., Donegani E., and Solinas A. A randomized controlled trial of interferon alfa-2b as therapy for chronic non-A, non-B hepatitis. J. Hepatol. 11 Suppl. 1 (1990) S43-S49
14. Poynard T., Moussalli J., Ratziu V., Regimbeau C., and Opolon P. Effect of interferon therapy on the natural history of hepatitis C virus-related cirrhosis and hepatocellular carcinoma. Clin. Liver Dis. 3 (1999) 869-881
15. Gomez-Rubio M., Porres J.C., Castillo I., Quiroga J.A., Moreno A., and Carreno V. Prolonged treatment (18 months) of chronic hepatitis C with recombinant alpha-interferon in comparison with a control group. J. Hepatol. 11 Suppl. 1 (1990) S63-S67
16. Bresci G., Parisi G., Banti S., and Bertoni M. Therapy of active chronic hepatitis with recombinant alpha 2b-interferon: an 18 month follow-up. Eur. J. Med. 2 (1993) 349-352
17. Chang T.W., and Heel R.C. Ribavirin and inosiplex: a review of their present status in viral diseases. Drugs 22 (1981) 111-128
18. Austin R.K., Trefts P.E., Hintz M., Connor J.D., and Kagnoff M.F. Sensitive radioimmunoassay for the broad-spectrum antiviral agent ribavirin. Antimicrob. Agents Chemother. 24 (1983) 696-701
19. Fernandez H., Banks G., and Smith R. Ribavirin: a clinical overview. Eur. J. Epidemiol. 2 (1986) 1-14
20. Braconier J.H., Paulsen O., Engman K., and Widell A. Combined alpha-interferon and ribavirin treatment in chronic hepatitis C: a pilot study. Scand. J. Infect. Dis. 27 (1995) 325-329
21. Brillanti S., Miglioli M., and Barbara L. Combination antiviral therapy with ribavirin and interferon alfa in interferon alfa relapsers and non-responders: Italian experience. J. Hepatol. 23 Suppl. 2 (1995) 13-15
22. Chemello L., Cavalletto L., Bernardinello E., Guido M., Pontisso P., and Alberti A. The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C. J. Hepatol. 23 Suppl. 2 (1995) 8-12
23. Schalm S.W., Hansen B.E., Chemello L., Bellobuono A., Brouwer J.T., Weiland O., Cavalletto L., Schvarcz R., Ideo G., and Alberti A. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers. J. Hepatol. 26 (1997) 961-966
24. Brown J.L. Efficacy of combined interferon and ribavirin for treatment of hepatitis C. Lancet 351 (1998) 78-79
25. Davis G.L., Esteban-Mur R., Rustgi V., Hoefs J., Gordon S.C., Trepo C., Shiffman M.L., Zeuzem S., Craxi A., Ling M.H., and Albrecht J. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N. Engl. J. Med. 339 (1998) 1493-1499
26. McHutchison J.G., Gordon S.C., Schiff E.R., Shiffman M.L., Lee W.M., Rustgi V.K., Goodman Z.D., Ling M.H., Cort S., and Albrecht J.K. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N. Engl. J. Med. 339 (1998) 1485-1492
27. Poynard T., Marcellin P., Lee S.S., Niederau C., Minuk G.S., Ideo G., Bain V., Heathcote J., Zeuzem S., Trepo C., and Albrecht J. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 352 (1998) 1426-1432
28. Davis G.L. Combination treatment with interferon and ribavirin for chronic hepatitis C. Clin. Liver Dis. 3 (1999) 811-826
29. Lau J., Tam R.C., Liang T.J., and Hong Z. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 35 (2002) 1002-1009
30. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Goncales Jr. F.L., Haussinger D., Diago M., Carosi G., Dhumeaux D., Craxi A., Lin A., Hoffman J., and Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347 (2002) 975-982
31. Barnard D.L. Pegasys (Hoffmann-La Roche). Curr. Opin. Investig. Drugs 2 (2001) 1530-1538
32. Ahn J., and Flamm S. Peginterferon-alpha(2b) and ribavirin. Expert. Rev. Anti. Infect. Ther. 2 (2004) 17-25
33. Heathcote E.J., Shiffman M.L., Cooksley W.G., Dusheiko G.M., Lee S.S., Balart L., Reindollar R., Reddy R.K., Wright T.L., Lin A., Hoffman J., and De Pamphilis J. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N. Engl. J. Med. 343 (2000) 1673-1680
34. Reddy K.R., Wright T.L., Pockros P.J., Shiffman M., Everson G., Reindollar R., Fried M.W., Purdum III P.P., Jensen D., Smith C., Lee W.M., Boyer T.D., Lin A., Pedder S., and DePamphilis J. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 33 (2001) 433-438
35. Zeuzem S., Feinman S.V., Rasenack J., Heathcote E.J., Lai M.Y., Gane E., O'Grady J., Reichen J., Diago M., Lin A., Hoffman J., and Brunda M.J. Peginterferon alfa-2a in patients with chronic hepatitis C. N. Engl. J. Med. 343 (2000) 1666-1672
36. Shepherd J., Brodin H., Cave C., Waugh N., Price A., and Gabbay J. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Health Technol. Assess. 8 (2004) 1-125
37. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., Goodman Z.D., Koury K., Ling M., and Albrecht J.K. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358 (2001) 958-965
38. Fried M.W. Side effects of therapy of hepatitis C and their management. Hepatology 36 (2002) 237-244
39. Dienstag J.L., and McHutchison J.G. American gastroenterological association medical position statement on the management of hepatitis C. Gastroenterology 130 (2006) 225-230
40. Dienstag J.L., and McHutchison J.G. American gastroenterological association technical review on the management of hepatitis C. Gastroenterology 130 (2006) 231-264
41. A.N.A.E.S. Consensus Conference. Treatment of hepatitis C. Gastroenterol. Clin. Biol. 26 Spec No 2 (2002) B303-B320
42. Davis G.L., Wong J.B., McHutchison J.G., Manns M.P., Harvey J., and Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 38 (2003) 645-652
43. Ferenci P. Predictors of response to therapy for chronic hepatitis C. Semin. Liver Dis. 24 Suppl. 2 (2004) 25-31
44. Ferenci P., Fried M.W., Shiffman M.L., Smith C.I., Marinos G., Goncales Jr. F.L., Haussinger D., Diago M., Carosi G., Dhumeaux D., Craxi A., Chaneac M., and Reddy K.R. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J. Hepatol. 43 3 (2005) 425-433
45. McHutchison J.G., Shad J.A., Gordon S.C., Morgan T.R., Ling M.H., Garaud J.J., Albrecht J.K., and Dienstag J.L. Predicting response to initial therapy with interferon plus ribavirin in chronic hepatitis C using serum HCV RNA results during therapy. J. Viral Hepat. 8 (2001) 414-420
46. Enomoto N., Sakuma I., Asahina Y., Kurosaki M., Murakami T., Yamamoto C., Ogura Y., Izumi N., Marumo F., and Sato C. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N. Engl. J. Med. 334 (1996) 77-81
47. Gale Jr. M., Blakely C.M., Kwieciszewski B., Tan S.L., Dossett M., Tang N.M., Korth M.J., Polyak S.J., Gretch D.R., and Katze M.G. Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation. Mol. Cell Biol. 18 (1998) 5208-5218
48. Berg T., von Wagner M., Nasser S., Sarrazin C., Heintges T., Gerlach T., Buggisch P., Goeser T., Rasenack J., Pape G.R., Schmidt W.E., Kallinowski B., Klinker H., Spengler U., Martus P., Alshuth U., and Zeuzem S. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 130 (2006) 1086-1097
49. Jensen D.M., Morgan T.R., Marcellin P., Pockros P.J., Reddy K.R., Hadziyannis S.J., Ferenci P., Ackrill A.M., and Willems B. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 43 (2006) 954-960
50. Mangia A., Santoro R., Minerva N., Ricci G.L., Carretta V., Persico M., Vinelli F., Scotto G., Bacca D., Annese M., Romano M., Zechini F., Sogari F., Spirito F., and Andriulli A. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N. Engl. J. Med. 352 (2005) 2609-2617
51. Sanchez-Tapias J.M., Diago M., Escartin P., Enriquez J., Romero-Gomez M., Barcena R., Crespo J., Andrade R., Martinez-Bauer E., Perez R., Testillano M., Planas R., Sola R., Garcia-Bengoechea M., Garcia-Samaniego J., Munoz-Sanchez M., and Moreno-Otero R. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 131 (2006) 451-460
52. Davis G.L. Tailoring antiviral therapy in hepatitis C. Hepatology 43 (2006) 909-911
53. Davis G.L. Monitoring of viral levels during therapy of hepatitis C. Hepatology 36 (2002) S145-S151
54. Shiffman M.L., Hofmann C.M., Contos M.J., Luketic V.A., Sanyal A.J., Sterling R.K., Ferreira-Gonzalez A., Mills A.S., and Garret C. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology 117 (1999) 1164-1172
55. Camma C., Di Bona D., Schepis F., Heathcote E.J., Zeuzem S., Pockros P.J., Marcellin P., Balart L., Alberti A., and Craxi A. Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data. Hepatology 39 (2004) 333-342
56. Kelleher T.B., and Afdhal N. Maintenance therapy for chronic heptitis C. Curr. Gastroenterol. Rep. 7 (2005) 50-53
57. Masci P., Bukowski R.M., Patten P.A., Osborn B.L., and Borden E.C. New and modified interferon alfas: preclinical and clinical data. Curr. Oncol. Rep. 5 (2003) 108-113